Bicara announces promising Phase 1b ficerafusp alfa results

Bicara Therapeutics Inc. ( (BCAX) ) has issued an update.

On February 19, 2026, Bicara Therapeutics reported preliminary results from an exploratory Phase 1b expansion cohort testing a higher, less-frequent 2000mg every-other-week dosing of ficerafusp alfa with pembrolizumab in first-line HPV-negative recurrent or metastatic head and neck squamous cell carcinoma. The data presented at the 2026 Multidisciplinary Head and Neck Cancers Symposium showed rapid, deep and durable responses with a safety profile consistent with prior experience, including a 48% confirmed overall response rate, 26% complete response rate and 77% of responders achieving at least 80% tumor shrinkage.

Biomarker and pharmacokinetic findings indicated that the 2000mg Q2W regimen maintains robust TGF-β inhibition and immune activation comparable to the existing 1500mg weekly regimen, supporting development of a more convenient loading and every-three-week maintenance schedule. While the pivotal FORTIFI-HN01 trial continues to enroll patients globally on the weekly dosing, the new data suggest a potential path to a less burdensome regimen that could enhance patient experience without sacrificing efficacy, reinforcing Bicara’s competitive position in the evolving treatment landscape for HPV-negative head and neck cancer.

The most recent analyst rating on (BCAX) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Bicara Therapeutics Inc. stock, see the BCAX Stock Forecast page.

Spark’s Take on BCAX Stock

According to Spark, TipRanks’ AI Analyst, BCAX is a Neutral.

Overall score reflects a strong solvency position and positive clinical/program milestones, partially offset by the lack of revenue and rapidly increasing losses/free-cash-flow burn. Technicals are mildly weak/neutral and valuation metrics offer limited support due to ongoing unprofitability.

To see Spark’s full report on BCAX stock, click here.

More about Bicara Therapeutics Inc.

Bicara Therapeutics Inc. is a Boston-based, clinical-stage biopharmaceutical company focused on developing transformative bifunctional therapies for solid tumors. Its lead product candidate, ficerafusp alfa, is a first-in-class bifunctional antibody targeting EGFR and trapping TGF-β to improve tumor penetration and deliver deep, durable responses, initially in head and neck squamous cell carcinoma but with potential across multiple solid tumor types.

Ficerafusp alfa has received U.S. FDA Breakthrough Therapy Designation in combination with pembrolizumab for first-line treatment of certain recurrent or metastatic head and neck squamous cell carcinoma patients. The company is advancing the drug through its pivotal FORTIFI-HN01 Phase 2/3 trial, aiming to address significant unmet needs in HPV-negative head and neck cancers and other difficult-to-treat solid tumors.

Average Trading Volume: 539,179

Technical Sentiment Signal: Sell

Current Market Cap: $771.3M

For an in-depth examination of BCAX stock, go to TipRanks’ Overview page.